Microglia inhibitor stops neuronal cell death after TBIResearchers at Trinity College in Dublin have demonstrated that resetting brain-specific immune cells improves traumatic brain injury (TBI) recovery. more ➔
Post-Brexit budget drives cuts in Horizon EuropeNegotiations of the EU Council on the EU’s seven-year budget have failed, putting R&D funding at risk for significant cuts. more ➔
Royal DSM acquires Glycom A/S for €765mRoyal DSM NV has entered the growing market of human milk oligosaccharides (HMO) taking over the producer of recombinant 2′-fucosyl lactose, Danish Glycom A/S. more ➔
Immatics Biotechnologies lands €1.1bn deal with GSKUS-German immunooncology specialist Immatics Biotechnologies GmbH has licensed two of its TCR-T programs to GlaxoSmithKline for US$50m upfront. more ➔
KKR backs Belgian tech provider Univercells SA Univercells S.A. cashes in up to €50m from the KKR subsidiary Gamma Bioscience to advance its gene and cell therapy manufacturing platform. more ➔
EU diagnostic labs prepared for Sars-CoV-2Shortly before a EU health ministers discuss the spread of the Chinese coronavirus, EU diagnostic labs have considered themselves prepared for a possible Sars-CoV-2 epidemic. more ➔
PharmaMar/Jazz Pharmaceuticals get NDA priority for lung cancer drugPharmaMar and Jazz Pharmaceuticals have received FDA Priority Review of a NDA for lurbinectedin in relapsed SCLC (Small Cell Lung Cancer). more ➔
Diabetes combo improves regeneration of beta cellsUsing a combination of approved diabetes drugs, a Swiss-US research team was able to support the regeneration of insulin-secreting cells in the pancreas. more ➔
JAKPot for treating bone loss Researchers report that JAK inhibitors – a class of approved anti-inflammatory drugs – prevented bone loss in mice with osteoporosis and two patients with rheumatoid arthritis. more ➔
Mereo BioPharma raise money to back Phase III trialsMereo BioPharma has entered into a $5m convertible equity financing with Novartis and a $28m securities purchase agreement with Aspire Capital Fund. more ➔
